Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;17(2):123-127.
doi: 10.4274/tjod.galenos.2020.90699. Epub 2020 Jul 29.

Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer

Özlem Ercelep  1 , Deniz Tataroğlu  1 , Melike Özçelik  1 , Heves Sürmeli  1 , Mustafa Değirmenci  2 , Mevlüde İnanç  3 , Mehmet Aliustaoğlu  1 , Mahmut Gümüş  4
Affiliations

Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer

Özlem Ercelep et al. Turk J Obstet Gynecol. 2020 Jun.

Abstract

Objective: To evaluate the efficacy of bevacizumab a monoclonal, antivascular endothelial growth factor antibody in combination with cytotoxic chemotherapy in Turkish patients with recurrent and metastatic cervical cancer.

Materials and methods: Data of 64 patients with metastatic or recurrent cervical cancer, receiving bevacizumab with first-line cisplatin or carboplatin and paclitaxel chemotherapy between 2013 and 2017 were retrospectively evaluated.

Results: The mean age of the patients was 49 years (range, 28-68), the median follow-up time was 12 months (range, 2-53), the median progression-free survival (PFS) was eight months, and the median overall survival (OS) was 23 months. All 64 patients received a median of 6 (range, 1-12) bevacizumab and 6 (range, 2-12) chemotherapy cycles. The chemotherapy regimens used with bevacizumab were cisplatin and paclitaxel in 31 (48%) and carboplatin and paclitaxel in 33 (52%) patients. The survival in patients treated with bevacizumab and cisplatin plus paclitaxel was better-particularly in patients with no previous cisplatin-based radiosensitizer therapy-than those treated with carboplatin, paclitaxel, and bevacizumab (p=0.023). The bevacizumab dose was 7.5 mg/kg in 30 patients (47%) and 15 mg/kg in 34 patients (53%) every 21 days. No significant difference was reported in the OS and the PFS between the two groups. While the most common all-grades adverse events were nausea, neutropenia, anemia, and peripheral sensory neuropathy, the most common grade ≥3 adverse events were neutropenia, anemia, and peripheral sensory neuropathy.

Conclusion: Adding bevacizumab to platinum and paclitaxel chemotherapy in a case of metastatic or recurrent cervical cancer is an effective and tolerable treatment for Turkish patients.

Keywords: Cervical cancer; bevacizumab; metastatic.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No conflict of interest was declared by the authors.

Figures

Figure 1
Figure 1
Overall survival according to chemotherapy regimen (prior chemoradiotherapy absent subgroup) OS: Overall survivol
Figure 2
Figure 2
Overall survival according to chemotherapy regimen (prior chemoradiotherapy present subgroup) OS: Overall survival
See this image and copyright information in PMC

References

    1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212. - PubMed
    1. Cervical cancer. Estimated incidence, mortality and prevalence worldwide in 2012. (Accessed on March 18, 2015). [Internet] http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx .
    1. Monk BJ, Herzog TJ. The evolution of cost-effective screening and prevention of cervical carcinoma: Implications of the 2006 consensus guidelines and human papillomavirus vaccination. Am J Obstetric Gynecology. 2007;197:337–9. - PubMed
    1. Monk BJ, Tewari KSL. Chapter 3: Invasive cervical cancer, in DiSaia PJ, Creasman WT (eds): Clinical Gynecologic Oncology (ed 7) New York, NY, Mosby, Inc. 2007;. pp.:55–124.
    1. Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: State of the art and future directions. J Clin Oncol. 2007;25:2952–65. - PubMed

LinkOut - more resources